« Previous Next » International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 2 , Pages 477-484 , 1 February 2010

A Prospective Randomized Trial to Study the Impact of Pretreatment FDG-PET for Cervical Cancer Patients With MRI-Detected Positive Pelvic but Negative Para-Aortic Lymphadenopathy

Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA, USA, Nov 5–9, 2006.

Chien-Sheng Tsai, M.D.
- Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
- Department of Medical Imaging and Radiological Science, Chang Gung University, School of Medicine, Taoyuan, Taiwan
Chyong-Huey Lai, M.D.
- Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
Ting-Chang Chang, M.D.
- Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
Tzu-Chen Yen, M.D.
- Department of Nuclear Medicine, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
Koon-Kwan Ng, M.D.
- Department of Diagnostic Radiology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
Swei Hsueh, M.D.
- Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
Steve P. Lee, M.D., Ph.D.
- Department of Radiation Oncology, University of California, Los Angeles, CA
Ji-Hong Hong, M.D., Ph.D.
- Department of Radiation Oncology, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan
- Department of Medical Imaging and Radiological Science, Chang Gung University, School of Medicine, Taoyuan, Taiwan
- Reprint requests to: Ji-Hong Hong, M.D. Ph.D., Department of Radiation Oncology, Chung Gung Memorial Hospital, #5, Fu-Shin St., KweiShan, Taoyuan, Taiwan, R.O.C. Tel: (886) 3-3282177; Fax: (886) 3-3280797

Received 4 July 2008 ,Revised 17 December 2008 ,Accepted 9 February 2009.

Trial profile of all randomized patients (n = case number).

Trial profile of all randomized patients (n = case number).
- Full-Size Image
- Download to PowerPoint
Overall survival curves for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group (n = 66) vs. control group (n = 63).

Overall survival curves for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group (n = 66) vs. control group (n = 63).
- Full-Size Image
- Download to PowerPoint
Disease-free survival curves for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group (n = 66) vs. control group (n = 63).

Disease-free survival curves for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group (n = 66) vs. control group (n = 63).
- Full-Size Image
- Download to PowerPoint
Curves for interval of freedom from distant metastasis for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group (n = 66) vs. control group (n = 63).

Curves for interval of freedom from distant metastasis for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group (n = 66) vs. control group (n = 63).
- Full-Size Image
- Download to PowerPoint
Overall survival curves for three subgroups: control group (n = 63), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group without extrapelvic metastases (n = 59), and FDG-PET group with

Overall survival curves for three subgroups: control group (n = 63), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) group without extrapelvic metastases (n = 59), and FDG-PET group with extrapelvic metastases (n = 7).
- Full-Size Image
- Download to PowerPoint